Transcend Capital Advisors LLC Sells 3,158 Shares of Stryker Corporation $SYK

Transcend Capital Advisors LLC trimmed its position in shares of Stryker Corporation (NYSE:SYK) by 31.3% in the 4th quarter, Holdings Channel.com reports. The firm owned 6,916 shares of the medical technology company’s stock after selling 3,158 shares during the quarter. Transcend Capital Advisors LLC’s holdings in Stryker were worth $2,431,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Clayton Financial Group LLC bought a new position in Stryker during the third quarter valued at $26,000. United Financial Planning Group LLC bought a new position in Stryker during the third quarter valued at $27,000. Strive Asset Management LLC bought a new position in Stryker during the third quarter valued at $30,000. ANTIPODES PARTNERS Ltd bought a new position in Stryker during the third quarter valued at $34,000. Finally, Copia Wealth Management grew its holdings in Stryker by 181.6% during the third quarter. Copia Wealth Management now owns 107 shares of the medical technology company’s stock valued at $40,000 after purchasing an additional 69 shares during the period. 77.09% of the stock is owned by institutional investors.

Stryker Price Performance

Stryker stock opened at $347.28 on Tuesday. Stryker Corporation has a one year low of $319.32 and a one year high of $404.87. The business has a fifty day moving average price of $354.45 and a 200-day moving average price of $360.24. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.89 and a quick ratio of 1.21. The firm has a market capitalization of $133.00 billion, a P/E ratio of 41.34, a PEG ratio of 1.98 and a beta of 0.92.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 EPS for the quarter, topping analysts’ consensus estimates of $4.40 by $0.07. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The firm had revenue of $7.17 billion during the quarter, compared to analyst estimates of $7.12 billion. During the same period last year, the company earned $4.01 earnings per share. The business’s revenue for the quarter was up 11.4% on a year-over-year basis. As a group, equities research analysts forecast that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Tuesday, March 31st. Stryker’s dividend payout ratio (DPR) is presently 41.90%.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 250,000 shares of the firm’s stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total value of $90,730,000.00. Following the completion of the transaction, the director directly owned 2,457,331 shares of the company’s stock, valued at $891,814,566.52. This trade represents a 9.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on SYK. Jefferies Financial Group reissued a “buy” rating and set a $465.00 price objective on shares of Stryker in a report on Wednesday, March 4th. Needham & Company LLC increased their price objective on Stryker from $448.00 to $454.00 and gave the company a “buy” rating in a report on Friday, January 30th. BTIG Research increased their price objective on Stryker from $410.00 to $412.00 and gave the company a “buy” rating in a report on Friday, January 30th. Piper Sandler reissued an “overweight” rating on shares of Stryker in a report on Tuesday, January 27th. Finally, Evercore set a $390.00 price objective on Stryker in a report on Monday, January 5th. Fifteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $422.53.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.